Summary: Bio-Rad Labs introduced the Vericheck ddPCR Empty-Full Capsid Kit, designed to determine capsid titer, genome titer, and the percentage of full capsids in AAV samples.
Takeaways:
- The Vericheck ddPCR Empty-Full Capsid Kit utilizes Bio-Rad’s Droplet Digital PCR technology to deliver precise, reproducible data from minimal AAV samples, including crude lysate or purified samples.
- This cost-effective kit streamlines AAV vector characterization processes, helping optimize gene therapy production and ensuring compliance with regulatory standards.
- The kit addresses the challenge of detecting product impurities like partial or empty capsids, aiding the development of safer, more effective gene therapies.
Bio-Rad Labs announced the launch of the Vericheck ddPCR Empty-Full Capsid Kit for the determination of capsid titer, genome titer, and percentage of full capsids in purified or unpurified (crude lysate) AAV samples.
Bio-Rad’s Capsid Kit
Using Bio-Rad’s Droplet Digital PCR technology, the new Vericheck ddPCR Empty-Full Capsid Kit analyzes minimal amounts of either crude lysate or purified samples to deliver robust, reproducible data for reliable assessment of AAV vector quality.
Designed for use on Bio-Rad’s Droplet Digital PCR Systems, the kit’s solution enables optimization of AAV vector characterization processes to streamline gene therapy development and production while supporting compliance with regulatory guidelines.
“AAV vectors are a powerful gene therapy tool, but their production can result in the generation of product-related impurities, such as partial or empty capsids, which impact effectiveness and can elicit unwanted immunotoxicity. Determining the ratio of full, partial, and empty capsids is a recurring challenge throughout AAV gene therapy manufacturing, from early-stage development to quality control and release testing,” says Stephen Kulisch, VP of marketing for Bio-Rad’s Digital Biology Group. “Our new Vericheck ddPCR Empty-Full Capsid Kit delivers unmatched precision and specificity, along with ease of use and high-throughput capabilities, to provide our customers with a comprehensive solution for AAV vector characterization and to help drive the advancement of safe and effective gene therapies.”
Photo: Bio-Rad